Q3 2026 Oncology Outlook: Key FDA Decisions to Watch

The third quarter of 2026 brings a fresh slate of high-stakes FDA decisions across breast cancer, melanoma, gastric cancer, hematologic malignancies, and lung cancer. Several of these actions represent carryover reviews that slipped from earlier in the year due to manufacturing questions or complete response letters, while others are entering review for the first time. Collectively, they underscore the oncology pipeline's continued emphasis on targeted therapies, antibody-drug conjugates, and cell-based immunotherapies for patients who have exhausted standard options.